NCE-1 Intelligence & Market Opportunity

Pyrukynd

Mitapivat

Antianemic

Oral Tablet

Approval Date

17-Feb-22

NCE-1 Date

17-Feb-26

NCE Date

17-Feb-27

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.8242

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

137

2027

310

2028

457

2029

598

2030

828

2031

993

2032

1162

Molecule profile

Details & specifications

Molecule

Mitapivat

Innovator

AGIOS PHARMACEUTICALS, INC.

Dosage Form

Oral Tablet

Strength

EQ 20 mg base, EQ 50 mg base, EQ 5 mg base, EQ 100 mg base

Therapeutic Category

Antianemic

Usage

To treat hemolytic anemia in pyruvate kinase deficiency

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.